BSE Live
Mar 30, 16:01Prev. Close
386.55
Open Price
390.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:56Prev. Close
386.15
Open Price
384.60
Bid Price (Qty.)
374.85 (84)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of SMS Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 | |
| Total Share Capital | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 | |
| Reserves and Surplus | 358.96 | 331.46 | 292.64 | 254.17 | 285.90 | |
| Total Reserves and Surplus | 358.96 | 331.46 | 292.64 | 254.17 | 285.90 | |
| Total Shareholders Funds | 367.42 | 339.92 | 301.11 | 262.63 | 294.36 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 68.22 | 58.96 | 71.40 | 74.22 | 113.23 | |
| Deferred Tax Liabilities [Net] | 39.74 | 30.62 | 23.00 | 15.85 | 44.90 | |
| Other Long Term Liabilities | 4.78 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 1.73 | 1.52 | 2.18 | 1.35 | 3.43 | |
| Total Non-Current Liabilities | 114.47 | 91.10 | 96.58 | 91.41 | 161.56 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 61.16 | 70.81 | 58.40 | 59.76 | 72.75 | |
| Trade Payables | 44.49 | 48.25 | 38.70 | 66.75 | 84.40 | |
| Other Current Liabilities | 38.84 | 26.02 | 23.64 | 19.95 | 40.37 | |
| Short Term Provisions | 0.72 | 0.72 | 0.72 | 0.54 | 2.90 | |
| Total Current Liabilities | 145.21 | 145.80 | 121.46 | 147.00 | 200.43 | |
| Total Capital And Liabilities | 627.10 | 576.82 | 519.14 | 501.04 | 656.35 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 279.65 | 280.11 | 278.90 | 290.04 | 369.95 | |
| Intangible Assets | 0.83 | 1.15 | 0.36 | 0.42 | 0.40 | |
| Capital Work-In-Progress | 42.12 | 18.30 | 8.20 | 7.76 | 12.80 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 322.61 | 299.56 | 287.46 | 298.21 | 383.15 | |
| Non-Current Investments | 45.00 | 45.00 | 45.00 | 36.98 | 21.27 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 2.13 | 2.01 | 1.90 | 4.37 | |
| Other Non-Current Assets | 40.71 | 22.55 | 16.19 | 6.58 | 0.00 | |
| Total Non-Current Assets | 408.32 | 369.23 | 350.66 | 343.68 | 408.79 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 129.20 | 136.40 | 107.48 | 92.52 | 112.68 | |
| Trade Receivables | 48.77 | 26.02 | 24.15 | 21.32 | 61.09 | |
| Cash And Cash Equivalents | 9.65 | 14.88 | 12.71 | 12.37 | 15.08 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 22.52 | |
| OtherCurrentAssets | 31.16 | 30.29 | 24.15 | 31.15 | 36.18 | |
| Total Current Assets | 218.78 | 207.59 | 168.49 | 157.36 | 247.55 | |
| Total Assets | 627.10 | 576.82 | 519.14 | 501.04 | 656.35 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 159.50 | 112.36 | 9.57 | 12.13 | 9.44 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 13.86 | 6.52 | 3.51 | 8.81 | 63.92 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 3.51 | 7.13 | 2.48 | 1.29 | 3.67 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.75 | 0.18 | 0.58 | 0.45 | 1.72 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | 0.28 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 98.10 | 60.29 | 64.45 | 50.14 | 152.66 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 2.42 | 2.42 | 2.42 | 2.42 | 2.42 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 45.00 | 45.00 | 45.00 | 36.98 | 21.27 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth